Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics

Abstract

Introduction

To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics.

Methods

A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was conducted to identify questions targeting specific barriers from validated adherence questionnaires. Once a finalized draft was complete, the risk assessment tool was built into an electronic survey where a risk category can be automatically calculated for the patient.

Results

The six most impactful factors affecting compliance to oral oncolytics were identified as patient's confidence, health literacy, perception of treatment, quality of life, social support, and complexity of chemotherapy regimen. A six-item questionnaire was created with five patient-directed questions and one clinician-directed question. Examples and descriptions were provided for clinicians to consider when categorizing complexity of a regimen. The tool was designed for responses to each question to be indexed into categories through a 10-point system. Results will be stratified into low, moderate, or high risk for nonadherence.

Conclusion

The creation of a tool to predict nonadherence prior to starting therapy is an unmet need for patients initiating oral oncolytics. The aim of this tool is to meet those needs and better guide clinicians to provide patients with strategies to better manage nonadherence. Next steps include tool validation and piloting in clinical practice.

Keywords

Oral oncolytics medication adherence oral chemotherapy adherence predictive tool

Get full access to this article

View all access options for this article.

References

Jacobs

Ream

Nisotel

. Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Canc Netw 2019; 17: 221–228.

Jimmy

Jose

. Patient medication adherence: measures in daily practice. Oman Med J 2011; 26: 155–159.

Ghiggia

Bianco

Castelli

, et al. Adherence to oral chemotherapy: evidence from a randomized clinical trial. Eur J Cancer Care 2021 Jan; 30(1): e13336. DOI: https://doi.org/10.1111/ecc.13336

Vyas

Descoteaux

Kogut

, et al. Predictors of adherence to oral anticancer medications: an analysis of 2010–2018 US nationwide claims. J Manag Care Pharm 2022; 28: 831–844.

National Community Oncology Dispensing Association. Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies, https://www.ncoda.org/oral-oncolytic-non-adherence-in-medically-integrated-dispensing-pharmacies/ (2022, accessed 10 February 2023).

Nassar

Basheti

Saini

. Exploring validated self-reported instruments to assess adherence to medications used: a review comparing existing instruments. Patient Prefer Adherence 2022; 16: 503–513.

Whooley

Cerecino

Weaver

, et al. Implementation of an oral chemotherapy adherence tool at an NCCN comprehensive cancer cencer. J Clin Oncol 2021; 39: 265. https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.265

Patel

Foster

Farrell

. Oral cancer chemotherapy adherence and adherence assessment tools: a report from north central cancer group trial N0747 and a systematic review of the literature. J Canc Educ 2013; 28: 770–776.

Burkhart

Sabaté

. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003; 35: 207. PMID: 14562485.

10.

Horne

Cooper

Gellaitry

, et al. Patients’ perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007; 45: 334–341.

11.

Brett

Fenlon

Boulton

, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl) 2018; 27. doi: https://doi.org/10.1111/ecc.12601. Epub 2016 Nov 30. PMID: 27901302.

12.

Kaptein

Schoones

van der Meer

, et al. Psychosocial determinants of adherence with oral anticancer treatment: ‘we don't need no education’. Acta Oncol 2021; 60: 87–95. Epub 2020 Nov 5. PMID: 33151764.

13.

Lea

Bohra

Moore

, et al. Exploring behaviors, treatment beliefs, and barriers to oral chemotherapy adherence among adult leukemia patients in a rural outpatient setting. BMC Res Notes 2018; 11: 43. PMID: 30497510; PMCID: PMC6267791.

14.

Salgado

Davis

Farris

, et al. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat 2017; 163: 311–319. Epub 2017 Mar 1. PMID: 28251384.

15.

Muluneh

Deal

Alexander

, et al. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. J Oncol Pharm Pract 2018; 24: 98–109. Epub 2016 Nov 30. PMID: 27895220.

16.

Pantuzza

Ceccato

MDGB

Silveira

, et al. Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. Eur J Clin Pharmacol 2017; 73: 1475–1489. Epub 2017 Aug 4. PMID: 28779460.

17.

Holden

Wheelwright

Harle

, et al. The role of health literacy in cancer care: a mixed studies systematic review. PLoS One 2021; 16: e0259815. PMID: 34767562; PMCID: PMC8589210.

18.

Miller

. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. Patient Educ Couns 2016; 99: 1079–1086. Epub 2016 Feb 1. PMID: 26899632; PMCID: PMC4912447.

19.

Wolf

Davis

Shrank

, et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 2007; 67: 293–300. Epub 2007 Jun 22. PMID: 17587533.

20.

DiMatteo

. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–209. PMID: 15076819.

21.

Kim

Kwon

Han

, et al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine (Baltimore) 2019; 98: e17825. PMID: 31804305; PMCID: PMC6919523.

22.

Partridge

Archer

Kornblith

, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28: 2418–2422. Epub 2010 Apr 5. PMID: 20368559; PMCID: PMC2881723.

23.

Carrera

Kantarjian

Blinder

. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018; 68: 153–165. Epub 2018 Jan 16. PMID: 29338071; PMCID: PMC6652174.

24.

Tran

Zafar

. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 2018; 6: 66. PMID: 29911114; PMCID: PMC5985271.

25.

Zafar

Peppercorn

Schrag

, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18: 381–390. Epub 2013 Feb 26. PMID: 23442307; PMCID: PMC3639525.

26.

Davis

Trickey

Abrahamse

, et al. Association of cumulative social risk and social support with receipt of chemotherapy among patients with advanced colorectal cancer. JAMA Netw Open 2021; 4: e2113533. PMID: 34106262; PMCID: PMC8190628.

27.

Trevino

Fasciano

Prigerson

. Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer. J Clin Oncol 2013; 31: 1683–1689. Epub 2013 Mar 25. PMID: 23530105; PMCID: PMC4878006.

28.

Alsabbagh

Lemstra

Eurich

, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health 2014; 17: 288–296. PMID: 24636389.

29.

Biggers

Shi

Charlson

, et al. Medicare D subsidies and racial disparities in persistence and adherence with hormonal therapy. J Clin Oncol 2016; 34: 4398–4404. Epub 2016 Oct 24. PMID: 27998232; PMCID: PMC5455308.

30.

Falagas

Zarkadoulia

Pliatsika

, et al. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008; 5: 13. PMID: 18241330; PMCID: PMC2267456.

31.

Lee

Park

Floyd

, et al. Combined effect of income and medication adherence on mortality in newly treated hypertension: nationwide study of 16 million person-years. J Am Heart Assoc 2019; 8: e013148. Epub 2019 Aug 17. PMID: 31422733; PMCID: PMC6759906.

32.

Tomic

Ventimiglia

Robinson

, et al. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer 2018; 142: 2478–2484. Epub 2018 Feb 2. PMID: 29363113; PMCID: PMC5947133.

33.

Academia

Mejías-De Jesús

Stevens

, et al. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies. J Manag Care Spec Pharm 2021; 27: 1438–1446. PMID: 34595953.

34.

McCabe

Barbee

Watson

, et al. Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies. Am J Health Syst Pharm 2020; 77: 1118–1127. PMID: 32537656.

35.

Hibbard

Mahoney

Stockard

, et al. Development and testing of a short form of the patient activation measure. Health Serv Res 2005; 40: 1918–1930. PMID: 16336556; PMCID: PMC1361231.

36.

Salgado

Mackler

Severson

, et al. The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices. Support Care Cancer 2017; 25: 1797–1807. Epub 2017 Jan 20. PMID: 28108821.

37.

Morris

MacLean

Chew

, et al. The single item literacy screener: evaluation of a brief instrument to identify limited Reading ability. BMC Fam Pract 2006; 7: 21. PMID: 16563164; PMCID: PMC1435902.

38.

McHorney

. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009; 25: 215–238. PMID: 19210154.

39.

Pincus

Yazici

Bergman

. RAPID3, An index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 2009; 35: 773–778. PMID: 19962621.

40.

Kocalevent

Berg

Beutel

, et al. Social support in the general population: standardization of the Oslo Social Support Scale (OSSS-3). BMC Psychol 2018;6:31. PMID: 30016997; PMCID: PMC6050647.

41.

Alves-Conceição

Rocha

KSS

Silva

FVN

, et al. Medication regimen complexity measured by MRCI: a systematic review to identify health outcomes. Ann Pharmacother 2018; 52: 1117–1134. Epub 2018 May 13. PMID: 29756471.

42.

George

Phun

Bailey

, et al. Development and validation of the medication regimen complexity index. Ann Pharmacother 2004; 38: 1369–1376. Epub 2004 Jul 20. PMID: 15266038.

43.

Iuga

McGuire

. Adherence and health care costs. Risk Manag Healthc Policy 2014; 7: 35–44. PMID: 24591853; PMCID: PMC3934668.